Can new data give Lilly's Taltz one head start on Novartis' Cosentyx?
admin 23rd April 2019 Uncategorised 0Eli Lilly’s Taltz has followed Novartis rival Cosentyx into all the diseases it treats. But this time, Lilly wants to be first—and some new phase 3 data could help make that happen. Taltz nailed its endpoints in a spondyloarthritis trial, Lilly said, paving the way for a potential FDA approval.
More: Can new data give Lilly's Taltz one head start on Novartis' Cosentyx?
Source: fierce